Trials of antibiotics where data provided separately for patients with isolated colonic CD
| Author/ref | N (isolated colonic CD) | Comparator | Primary end point | Rifaximin remission rate | Placebo remission rate | p Value | Conclusions |
|---|---|---|---|---|---|---|---|
| Prantera et al150 | 190 active; 76 placebo (from online supplementary table S2) | Placebo | Week 12 remission (CDAI <150) | 3 doses: 400 mg twice daily; 800 mg twice daily; 1200 mg twice daily; no dose-response overall; pooled doses remission in 96/190 (51%) | 28/76 (37%) | 0.04 | Rifaximin more effective for colonic than ileal disease |
| (a) Controlled trial of oral rifaximin | |||||||
| Author/ref | N (isolated colonic CD) | Comparator | Primary end point | Metronidazole response rate | Placebo response rate | p Value | Conclusions |
| Blichfeldt et al151 | 6 | Placebo (crossover) | Week 8 response | 100% | 2/6 (33%) | NS overall | Metronidazole 1 g daily improved symptoms and lab values in all six with colonic disease |
| Sutherland et al152 | 12 (4 received 10 mg/kg; 4 received 20 mg/kg; placebo) | Placebo | Week 16 response | Mean CDAI drop 145, 95% CI 26 to 265, n=8 | CDAI increased by mean of 61, n=4 | 0.05 | Metronidazole more effective than placebo in colonic and ileocolonic disease but not small bowel disease |
| (b) Controlled trials of oral metronidazole | |||||||
CD, Crohn's disease; NS, not significant.